Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK/Beclin1-mediated autophagy.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer letters"
DOI: 10.1016/j.canlet.2021.09.010
Abstract: Colorectal cancer (CRC) is one of the most common malignancies worldwide, and effective therapy remains a challenge. In this study, we take advantage of a drug repurposing strategy to screen small molecules with novel anticancer… read more here.
Keywords: suppresses colorectal; lomitapide; activation; targeting pp2a ... See more keywords
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Genetics"
DOI: 10.3389/fgene.2022.937750
Abstract: Background and aim: Autosomal recessive hypercholesterolemia (ARH) is a rare autosomal recessive disorder of low-density lipoprotein (LDL) metabolism caused by pathogenic variants in the LDLRAP1 gene. Like homozygous familial hypercholesterolemia, ARH is resistant to conventional… read more here.
Keywords: lomitapide; recessive hypercholesterolemia; treatment; autosomal recessive ... See more keywords
Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Atherosclerosis and Thrombosis"
DOI: 10.5551/jat.le003
Abstract: Address for correspondence: Mariko Harada-Shiba, Cardiovascular Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki City, Osaka 569-8686 E-mail: [email protected] Received: May 6, 2022 Accepted for publication: May 7, 2022 Pa t i e n… read more here.
Keywords: day; period; patients hofh; hypercholesterolemia ... See more keywords